Healthcare of Ontario Pension Plan Trust Fund increased its position in Stoke Therapeutics, Inc. (NASDAQ: STOCK)

Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 426.1% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 1,387,200 shares of the company’s stock after buying an additional 1,123,500 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Stoke Therapeutics were worth $18,741,000 at the end of the most recent reporting period.

Other institutional investors have added to or reduced their stakes in the company. Quest Partners LLC purchased a new position in Stoke Therapeutics in the second quarter valued at approximately $29,000. Nisa Investment Advisors LLC boosted its holdings in shares of Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Stoke Therapeutics in the second quarter valued at about $123,000. Board of Trustees of Florida Retirement System purchased a new position in shares of Stoke Therapeutics in the first quarter valued at approximately $141,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after purchasing an additional 1,994 shares during the last quarter.

Stoke Therapeutics fell 3.1%

STOK opened at $11.81 on Friday. Stoke Therapeutics, Inc. it has a 52-week low of $3.35 and a 52-week high of $17.58. The company has a fifty day simple moving average of $14.17 and a 200 day simple moving average of $13.46. The firm has a market cap of $615.55 million, a P/E ratio of -4.90 and a beta of 0.96.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report ) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The business had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million. Sell-side analysts expect that Stoke Therapeutics, Inc. to post -2.1 earnings per share for the current year.

Changes in Analyst Ratings

A number of brokerages have recently issued reports on STK. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, September 11th. Finally, Wedbush restated an “outperform” rating and set a $17.00 target price on shares of Stoke Therapeutics in a research note on Thursday, July 11th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.40, according to MarketBeat.

Get the latest research report on STK

Insider trading at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. The transaction was disclosed in a filing with the SEC, which is accessible via this link. Insiders own 11.30% of the company’s shares.

Stoke Therapeutics Company Profile

(Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company uses its proprietary targeted amplification of nuclear gene production to develop antisense oligonucleotides to selectively restore protein levels.

Featured stories

Want to see what other hedge funds STK owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report).

Get news and reviews for Stoke Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Stoke Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.